Severe COVID pneumonia and undetectable B cells after vaccination in patients previously treated with rituximab: a case series.
Postgrad Med
; 134(2): 239-243, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1671777
ABSTRACT
INTRODUCTION:
The risk of developing severe COVID-19 illness despite completing vaccination for patients who have previously received immunosuppressive therapy is unclear. CASE PRESENTATION We present three patients who received rituximab for treatment of autoimmune disorders who subsequently developed severe COVID-19 pneumonia post-vaccination requiring intensive care unit admission and found to have undetectable B cells.DISCUSSION:
While there have been concerns about the effectiveness of COVID-19 vaccines in this patient cohort, this is the first case series to report development of severe COVID-19 illness after completing vaccination in those who previously received rituximab. Guidelines for the optimal timing of COVID-19 vaccination in relation to immunosuppressive therapy have been recently published, albeit after many patients in this subpopulation have already been vaccinated.CONCLUSION:
This case series brings attention to the limited humoral response to vaccines in patients treated with rituximab, highlights existing guidelines and their limitations, and raises future considerations about the potential benefits to testing vaccine responsiveness.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Vacunas contra la COVID-19
/
COVID-19
Tipo de estudio:
Reporte de caso
/
Estudio de cohorte
/
Estudio observacional
/
Estudio pronóstico
Tópicos:
Vacunas
Límite:
Humanos
Idioma:
Inglés
Revista:
Postgrad Med
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
00325481.2022.2037359
Similares
MEDLINE
...
LILACS
LIS